Can product pipeline innovation combat antibiotic resistance?

With the rapid emergence of microbial resistance to many drugs that were used to treat common infections, the world seems to be sliding towards pre-antibiotic era where all infections remained untreatable


Dr Nata Menabde, WHO Representative to India

For combating antimicrobial resistance (AMR), the biotech and the biopharmaceutical companies have to innovate better therapeutic tools to fight back the drug resistance. Especially, pharma companies should have new and improved drug pipeline to stay prepared for any outbreaks.

Companies can consider partnering with research-based organizations and other science promoting agencies, and to actively work towards promoting public health awareness, and rational prescription of antibiotics by physicians.

Antimicrobial resistance occurs when microorganisms such as bacteria, viruses, fungi and parasites change in ways that renders the medications ineffective.

Faulty Practices

‘Antimicrobial resistance' is the broader term for resistance in different types of microorganisms, and encompasses resistance to antibacterial, antiviral, antiparasitic and antifungal drugs.


Previous 1 3 4 5 6 7 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email